Evidence map›Paper›PMID 26444018›Full record

ArticleBMC musculoskeletal disorders2015

Hyaluronic acid increases tendon derived cell viability and collagen type I expression in vitro: Comparative study of four different Hyaluronic acid preparations by molecular weight.

Leonardo Osti, Martina Berardocco, Viviana di Giacomo, Graziella Di Bernardo, Francesco Oliva, Anna C Berardi

Erratum issuedOpen access · goldAbstract readComparative Study
In one paragraph

Article in BMC musculoskeletal disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Leonardo OstiUnit of Arthoscopy and Sports Trauma Surgery, Hesperia Hospital, Modena, Italy. leonardoosti@yahoo.com.
Martina BerardoccoU.O.C. of Immunohaematology and Transfusion Medicine, Laboratory of Stem Cells, Spirito Santo Hospital, via Fonte Romana 8, 65125, Pescara, Italy. martina.berardocco@gmail.com.
Viviana di GiacomoDepartment of Pharmacy, University G. d'Annunzio, Chieti, Italy. v.digiacomo@unich.it.
Graziella Di BernardoU.O.C. of Immunohaematology and Transfusion Medicine, Santo Spirito Hospital, Pescara, Italy. graziella.dibernardo@ausl.pe.it.
Francesco OlivaDepartment of Orthopedics and Traumatology, University of Rome "Tor Vergata" School of Medicine, Rome, Italy. olivafrancesco@hotmail.com.
Anna C BerardiU.O.C. of Immunohaematology and Transfusion Medicine, Laboratory of Stem Cells, Spirito Santo Hospital, via Fonte Romana 8, 65125, Pescara, Italy. annacberardi@yahoo.it.
Ospedale di Santo Spirito · ITHesperia Hospital · ITUniversity of Chieti-Pescara · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyaluronic Acid (HA) has been already approved by Food and Drug Administration (FDA) for osteoarthritis (OA), while its use in the treatment of tendinopathy is still debated. The aim of this study was to evaluate in human rotator cuff tendon derived cells the effects of four different HA on cell viability, proliferation, apoptosis and the expression of collagen type I and collagen type III.

methodsAn in vitro model was developed on human tendon derived cells from rotator cuff tears to study the effects of four different HA preparations (Ps) (sodium hyaluronate MW: 500-730 KDa - Hyalgan®, 1000 kDa Artrosulfur HA®, 1600 KDa Hyalubrix® and 2200 KDa Synolis-VA®) at various concentrations. Tendon derived cells morphology were evaluated after 0, 7 and 14 d of culture. Viability, proliferation, apoptosis were evaluated after 0, 24 and 48 h of culture. The expression and deposition of collagen type I and collagen type III were evaluated after 1, 7 and 14 d of culture.

resultsAll HAPs tested increased viability and proliferation, in dose dependent manner. HAPs already reduce apoptosis at 24 h compared to control cells (without HAPs). Furthermore, HAPs stimulated the synthesis of collagen type I in a dose dependent fashion over 14 d, without increase in collagen type III; moreover, in the presence of Synolis-VA® the expression and deposition of collagen type I was significantly higher as compare with the other HAPs.

conclusionsHAPs enhanced viability, proliferation and expression of collagen type I in tendon derived cells.

Indexed as

ApoptosisCells, CulturedCell SurvivalCollagen Type IFluorescent Antibody TechniqueHumansHyaluronic AcidMolecular WeightRotator Cuff InjuriesTendinopathyTendonsViscosupplementsCollagen Type IHyaluronic AcidViscosupplements

Identifiers

PMID26444018
PMCPMC4596363
OpenAlexW2137633938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.